eLetters

46 e-Letters

published between 2010 and 2013

  • Response
    Malik Y Kahook

    We would like to thank Zaidi et al. for their interest in our publication titled, "Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents." [1] As stated in our publication, we believe anti-VEGF agents revolutionized the treatment of ocular neovascular disease and their overall safety profile is excellent. The points by Zaidi et al. are valid and we take this opportunity to expand...

    Show More
  • respond
    Vannarut Satitpitakul

    In your September 2010 issue, I read with interest the article about amblyopia by D J Hwang.1 The group has also previously published a similar article in Korean Journal of Ophthalmology 2 but it was not mentioned in the references. Both articles included their participants from the same hospital since 2000 and the eligibility criteria were nearly identical. I was wondering if both articles share the same group of parti...

    Show More
  • Treatments for macular degeneration: summarising evidence using network meta-analysis
    Valeria Fadda

    Treatments for age-related macular degeneration (AMD) are lively being debated. One controversy is that all randomized controlled studies published thus far have used placebo or verteporfin in the control group [1,2]; hence, direct head-to-head comparisons between the newest active agents are lacking. The only randomised trial comparing ranibizumab vs bevacizumab (CATT study [3]) is still ongoing and its results are...

    Show More
  • Letter response to: The utility of relative afferent pupillary defect as a screening tool for glaucoma: prospective examination of a large population-based study in a south Indian population
    George Spaeth

    Dear Editor:

    The article by Hennessy and co-authors is important and interesting, and the last three words of the abstract are essential (The utility of relative afferent pupillary defect as a screening tool for glaucoma: prospective examination of a large population-based study in a south Indian population. BJO Online First, February 24, 2011, DOI: 10.1136/BJO. 2010.194217). Their conclusion is, "The authors...

    Show More
  • Author Response Re: "Need to further investigate the efficacy of valproic acid therapy in retinal degenerative disorders" letter
    Radouil Tzekov

    Dear Editor,

    We appreciate the interest of Dr. Kahn and Dr. Philip [1] in our paper describing pilot results from a retrospective study in patients with retinitis pigmentosa (RP) treated with valproic acid (VPA) [2], and we would like to comment on the points raised by them.

    Length of treatment. As mentioned in our recent reply to another letter regarding the same article [3], the length of treatment...

    Show More
  • Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy.
    Gerassimos Lascaratos

    We read with great interest the article by Kumar et al. We have audited our 1-year results using a slightly different clinical model: a nurse-led optical coherence tomography (OCT)-guided macula service.

    Following wet AMD diagnosis in the consultant-led macula clinic, three consecutive monthly ranibizumab injections are administered. Thereafter, patients are reviewed 4-6 weekly in the nurse-led clinic for 2 visi...

    Show More
  • Tissue plasminogen activator (tPA) and retinal vein occlusion
    Stefan Mennel

    Dear editor:

    Yamamoto and coworkers present in their paper the effect of simultaneous intravitreal injection of a mixture of 4mg triamcinolone acetonide (TA) and 25?g tissue plasminogen activator (tPA) to treat macular edema due to central retinal vein occlusion (CRVO) ?1?. The authors included 20 eyes. Best corrected visual acuity (BCVA) improved three lines or more in 65%, 55%, 55% and 53% of eyes and the mea...

    Show More
  • The Statistical Interpretation of the Coefficient of Repeatability
    James Loughman

    Bartlett et al. have reported on the clinical viability of the MPS 9000, a heterochromatic flicker photometry (HFP) device used to estimate macular pigment optical density (MPOD).[1] Coefficient of repeatability (CoR) values were used to determine the test-retest repeatability and reproducibility of the MPS 9000. While the observed CoR of 0.33 is indeed high, and, superficially at least, raises concern regarding the clin...

    Show More
  • Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents
    Ali A Zaidi

    We read with great interest the article by Good et al. titled "Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents." Authors of other case series have reported sustained intraocular pressure (IOP) elevation following bevacizumab and ranibizumab injections. Good et al. conducted a retrospective chart review of 215 eyes receiving anti-VEGF injections to answer the following ques...

    Show More
  • Case-control or cohort study?
    Ashutosh Tamhane

    To The Editor,

    In a recently published article by Chandra et al. the authors have stated that they conducted a "case-controlled" study to examine the anticoagulant effectiveness of warfarin in vitreoretinal surgery.(1) However, this study was conducted on a cohort of patients receiving pars plana vitrectomy (PPV); 60 patients who received warfarin (exposure) on the day of PPV were selected. These 'exposed' pati...

    Show More

Pages